Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
Eli Lilly's Alzheimer's drug Kisunla, under late-stage trials, shows promising interim results with a gradual dosing schedule, reducing serious brain swelling cases. The trial, which is under review ...